Could a seizure drug also prevent sudden death in dravet syndrome?
NCT ID NCT07112365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug Fintepla (fenfluramine) can improve how the brain and lungs respond to carbon dioxide in people with Dravet syndrome, a severe epilepsy. Poor responses to CO2 may increase the risk of sudden unexpected death in epilepsy (SUDEP). Twenty-five participants will take Fintepla for about 60 days and undergo brain scans and breathing tests to measure changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fenfluramine (Fintepla)
What this could lead to
If it works, this could point toward a way to lower the risk of sudden unexpected death in epilepsy (SUDEP) for people with Dravet syndrome.
What could go wrong
This is a small, early-stage study with only 25 participants, so results may not apply to everyone. It focuses on brain and breathing changes, not directly on preventing death, so benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••